VJOncology Podcast

In this week’s VJOncology podcast, we explore the latest developments in neuro-oncology, including emerging approaches in immunotherapy, PARP inhibition, and radioligand therapy. Join Nicholas Blondin and Sylvia Kurz of Yale University School of Medicine, New Haven, CT, Martin Hojgaard of Rigshospitalet, Copenhagen, Denmark, Tolga Tuncer of the University of Kansas Medical Center, Kansas, KC, and Dinu Stefan of François Baclese Cancer Center, Caen, France, as they discuss key ASCO findings, including the MAGMA and ROADS trials, lutetium-177 dotatate in meningioma, the molecular landscape of MTAP deletions, neoantigen-specific T-cell therapy for glioblastoma, and intermittent olaparib combined with radiotherapy and temozolomide in high-grade gliomas.

In recognition of Gynecologic Cancer Awareness Month, this episode of VJOncology podcasts explores recent advances shaping the treatment and diagnosis of gynecologic cancer. Join leading experts Linda Mileshkin of Peter MacCallum Cancer Center, Melbourne, Australia, Martin Hojgaard of Rigshospitalet, Copenhagen, Denmark, Claudia Marchetti of Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Rome, Italy, and Shailendra Dandge of the Society for Health Allied Research Education India, Hyderabad, India, as they discuss key developments. They cover new data for novel therapeutics including puxitatug samrotecan and EIK1003, the prognostic effect of neoadjuvant chemotherapy in ovarian cancer and a community health volunteer-led intervention to improve cervical cancer screening participation in low-resource settings.

In this week’s VJOncology podcast, we explore recent advances in therapeutic radiopharmaceuticals for metastatic castration-resistant prostate cancer, including emerging alternatives to lutetium-177. Join Jeremie Calais of University of California, Los Angeles, CA, Pedro Barata of Seidman Cancer Center, Cleveland, OH, and Enrique Gallardo of Parc Taulí University Hospital, Barcelona, Spain, as they discuss actinium-225-based PSMA-targeted radioligand therapies, findings from the CONVERGE-01, AcTION, and ProstACT Global trials, the expanding PSMA-targeted treatment landscape, and final overall survival results from PEACE-3.

On this week’s episode of VJOncology podcasts, we bring you head and neck cancer highlights in immuno-oncology from the 2026 ASCO Annual Conference. Join Barbara Burtness from the Yale School of Medicine, Hannah Kenny from Thomas Jefferson University Hospital, Ari Rosenberg from the University of Chicago, Nabil Saba from Emory University, and Kedar Kirtane from Moffitt Cancer Center as they discuss highlights from the meeting. They explore new data from key trials including OrigAMI-4, EV-202 and KEYNOTE-412, as well as emerging cellular therapies and checkpoint inhibitors.

In this week’s VJOncology podcast, we explore the latest advances in skin cancer from ASCO 2025, with a focus on melanoma and emerging cellular therapies. Join Alexandra Haugh of Massachusetts General Hospital Cancer Center, Boston, MA, Kalijn Bol of Radboud University Medical Center, Nijmegen, Netherlands, Allison Betof Warner of Stanford University, Stanford, CA, Omid Hamid of The Angeles Clinic and Research Institute, Los Angeles, CA, and Peter Forsyth of Moffitt Cancer Center, Tampa, FL, as they discuss real-world outcomes with lifileucel, treatment sequencing in BRAF-mutated melanoma, emerging cellular therapies and vaccines, and preclinical approaches to CAR T-cell therapy for leptomeningeal disease.

Welcome to another episode of VJOncology Podcast, featuring a roundtable discussion from iwCAR-T 2026, which took place in Tampa, FL. This week, our experts explore advances in tumor-infiltrating lymphocyte (TIL) therapy for solid tumors. Join Benjamin Creelan from Moffitt Cancer Center, Rodabe Amaria from the University of Texas MD Anderson Cancer Center, Daniel Olson from the University of Chicago, and Lilit Karapetyan from Moffitt Cancer Center as they discuss sequencing, duration issues and armoring approaches for TIL therapy in melanoma and other solid tumors.

In this week’s VJOncology podcast, we explore the latest developments in artificial intelligence (AI) in oncology and their potential to transform cancer care. Join Eleonora Teplinsky, Valley Health System, Paramus, NJ, Gil Shamai, Technion–Israel Institute of Technology, Haifa, Israel, Matthew Kurian, St. Elizabeth Healthcare, Edgewood, KY, Jai Patel, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC, and Marie Hanaoka, Institute of Science Tokyo, Japan, as they discuss AI-driven patient education, biomarker prediction, clinical decision-making, trial matching, and surgical training, alongside the opportunities and challenges of integrating artificial intelligence into oncology practice.

In this week’s VJOncology podcast, we present highlights in genitourinary cancer from the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. Join Andrew Armstrong of Duke University Medical Center, Srikala Sridhar of the Princess Margaret Cancer Centre, Tian Zhang of UT Southwestern Medical Center, and Lucia Nappi of the University of British Columbia as they discuss key data and clinical perspectives across prostate, bladder, kidney and testicular cancer, including the PROTEUS, CHAMP, TALAPRO-3, A-DREAM and SWOG S1823 trials, as well as the role of enfortumab vedotin and pembrolizumab in bladder cancer.

In this week’s VJOncology podcast, we had the opportunity to attend the 2026 ESMO Gastrointestinal Cancers Congress in Munich, Germany, where we explored the latest advances across gastrointestinal malignancies. Join Teresa Macarulla, Vall d’Hebron University Hospital, Barcelona, Spain, Giulia Martini, Università degli Studi della Campania Luigi Vanvitelli, Naples, Italy, Lorenza Rimassa, Hunimed University, Milan, Italy, Kohei Shitara, National Cancer Center Hospital East, Kashiwa, Japan, and Silvio Ken Garattini, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy, as they discuss emerging KRAS G12D-targeted therapies in pancreatic cancer, ctDNA-guided treatment strategies in metastatic colorectal cancer, novel targeted approaches for biliary tract cancer, HER2-directed therapies in gastroesophageal cancer, and evolving treatment paradigms in hepatocellular carcinoma and gastric cancer.

This week, VJOncology brings you lung cancer highlights from the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Join Alessandro di Federico from the Memorial Sloan Kettering Cancer Center, Erika Ruiz-Garcia of the Instituto Nacional de Cancerologia, Nandini Menon of the Tate Memorial Centre and Bjorn Henning Gronberg of the Norwegian University of Science and Technology as they discuss key trials and data in lung cancer from the meeting. They explore results from the LIBRETTO-432, TRITON and FLAME trials, as well as 7-year follow up data from the CROWN trial. In addition, they discuss two trials of KRAS G12C inhibitors, a study examining low-dose pembrolizumab and a trial of thoracic radiotherapy.

For this week’s VJOncology podcast, we bring you highlights in breast cancer from the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. Join Oleg Gluz of Evang. Krakenhaus “Bethesda” Klinik, Jana de Boniface of the Karolinska Institutet, Peter Schmid of Queen Mary University of London and Erika Hamilton of the Sarah Cannon Research Institute as they discuss key trials and what this means for clinical practice. They explore pooled analysis from the ADAPT and PlanB trials, results from the SENOMAC trial of axillary lymph node dissection omission, menopausal status data from the lidERA trial, final analysis from KEYNOTE-522 and subgroup analyses from HER2CLIMB-05.

In this week’s VJOncology podcast, we had the opportunity to attend the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL, where we explored the latest advances in gastrointestinal (GI) cancers. Join Ghassan Abou-Alfa and Yelena Janjigian of Memorial Sloan Kettering Cancer Center, Scott Kopetz of The University of Texas MD Anderson Cancer Center, and Choong-Kun Lee of Yonsei University as they discuss emerging treatment strategies in GI cancers, including findings from the EMERALD-3, RASolute 302, DESTINY-Gastric03, BREAKWATER, and HERBOT trials, alongside the growing role of targeted therapies, HER2-directed approaches, and biomarker testing in gastrointestinal oncology.

In this episode of VJOncology podcasts, we present highlights from the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. Five leading experts share key data and insights spanning prostate cancer, sarcoma, lung cancer, colorectal cancer, and breast cancer. Dr Mary-Ellen Taplin from Dana-Farber Cancer Institute presents final analysis data from the PROTEUS trial, demonstrating that perioperative apalutamide plus androgen deprivation therapy (ADT) sets a new standard of care in high-risk localized prostate cancer. Dr Maggie Zhou from Stanford University highlights practice-changing findings in sarcoma, including the SARC041 trial of abemaciclib in dedifferentiated liposarcoma. Dr Abdul Rafeh Naqash from the University of Oklahoma Health Sciences Center reviews key lung cancer advances, including results from the DeLLphi-304, LIBRETTO-432, and ALCHEMIST trials. Dr Scott Kopetz from MD Anderson Cancer Center presents progression-free and overall survival data from BREAKWATER Cohort 3, supporting encorafenib plus cetuximab combined with FOLFIRI as a new standard of care in BRAF V600E-mutant metastatic colorectal cancer. Finally, Dr Kevin Kalinsky from Emory University discusses PFS2 data from ASCENT-04, reinforcing sacituzumab govitecan plus pembrolizumab as a standard of care in treatment-naive PD-L1-positive metastatic triple-negative breast cancer. This episode offers essential insights into practice-changing data across five major tumor types from one of the most important oncology meetings of the year.

In this roundtable discussion from iwCAR-T 2026, a panel of experts in cell therapy for solid tumours discuss the current state of CAR T-cell therapy beyond hematological malignancies. The panel explores key challenges including target selection, T-cell persistence, and the immunosuppressive tumour microenvironment, alongside emerging strategies such as armoured CARs, combination approaches with targeted therapies, and in vivo CAR T-cell generation. The discussion also addresses the importance of patient selection and earlier lines of therapy, and considers how academic–industry partnerships and evolving manufacturing technologies may shape the future of the field.

In this week’s VJOncology podcast, we mark Bladder Cancer Awareness Month by exploring recent advances in bladder cancer research and clinical care. Join Joaquim Bellmunt of Dana-Farber Cancer Institute, Boston, MA, Eva Compérat of Medical University of Vienna, Vienna, Austria, Roberto Contieri of Humanitas University, Milan, Italy, and Vadim Koshkin of University of California, San Francisco, CA, as they discuss circulating tumor DNA for MRD monitoring in muscle-invasive bladder cancer, advances in intravesical therapies and urinary tract diagnostics, de-escalated approaches for low-grade non-muscle-invasive disease, and the evolving molecular classification of bladder cancer into luminal and basal subtypes.

In this week’s VJOncology podcast, we bring you key updates from the 2026 AACR meeting across early-phase immuno-oncology and targeted therapy. Join leading experts Bruno Bockorny, Beth Israel Deaconess Medical Center, Boston, MA, Byoung Chul Cho, Yonsei University, Seoul, South Korea, Kristen Pauken, and Timothy Yap, MD Anderson Cancer Center, Houston, TX, as they discuss the clinical challenges of immune-related adverse events with checkpoint inhibitors, early signals from first-in-human studies of PLN-101095 in refractory solid tumors, emerging safety and activity data from a Phase I dose-escalation study of denikitug, and updated results of elisrasib monotherapy in previously treated KRAS G12C-mutant non-small cell lung cancer.

In this week's instalment of the VJOncology podcast, we examine the rapidly evolving treatment landscape of advanced non-small cell lung cancer, drawing on expert insights from ELCC 2026. This episode spans the breadth of precision oncology in NSCLC: from the clinical challenges of rare actionable alterations and emerging targeted agents, to the growing complexity of first-line treatment sequencing, and the arrival of a promising new immunotherapy class in thoracic oncology. Leading clinicians and researchers from the Jules Bordet Institute, Princess Margaret Cancer Centre, Institut Curie, and Lausanne University Hospital discuss BRAF non-V600E mutations, KRAS G12C, HER2-mutant disease, EGFR exon 20 insertions, amivantamab-based combinations, and the evolving role of bispecific T-cell engagers in NSCLC and mesothelioma. This episode provides actionable insight for clinicians navigating an increasingly crowded and competitive treatment landscape in advanced NSCLC.

In this week’s VJOncology podcast, we mark Head and Neck Cancer Awareness Month by exploring recent advances in head and neck cancer. Join Kevin Harrington, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK, Takeshi Kodaira, Aichi Cancer Center, Nagoya, Japan, Andreas Dietz, University Hospital of Leipzig, Leipzig, Germany, and Nabil Saba, Emory University, Atlanta, GA, as they discuss key clinical trial updates, including OrigAMI-4, ASPEN-04, CompARE, and JCOG1912, alongside evolving strategies optimizing radiation dosing, reducing late toxicities, and improving management of recurrent respiratory papillomatosis.

In this week’s VJOncology podcast, we had the opportunity to attend the 2026 British Thoracic Oncology Group (BTOG) conference, where we explored key developments in lung cancer screening, diagnostics, and clinical research. Join Robert Rintoul, University of Cambridge, Cambridge, UK, Lauren Dixon, London School of Hygiene & Tropical Medicine, London, UK, Mariana Brandao, Jules Bordet Institute, Brussels, Belgium, and Anna Bibby, North Bristol NHS Trust, Bristol, UK as they discuss national screening updates, insights from the State of the Nation report, ongoing EORTC trials, and the clinical implications of incidental findings in lung cancer screening programs.

In this week’s VJOncology podcast, we had the opportunity to attend the 12th Immunotherapy of Cancer (ITOC) Conference, where we explored cutting-edge developments in cancer immunotherapy and tumor biology. Join David Giles of Washington University in St. Louis, MO, Bernard Fox of Providence Cancer Institute, Portland, OR, and Krijn Dijkstra of Netherlands Cancer Institute, Amsterdam, Netherlands as they discuss innovative approaches including live cell and dark antigen vaccines, adoptive cell therapy in melanoma, and tumor-intrinsic mechanisms shaping immune exclusion in colorectal cancer.

In this week’s VJOncology podcast, we will be covering highlights from ASCO GU 2026 in San Francisco, CA. Dive into the latest advancements in genitourinary cancers, including groundbreaking trial results and emerging treatment strategies. In this episode, join Enrique Gallardo, MD, Parc Taulí University Hospital, Barcelona, Spain, Jan-Jaap Mellema, MD, Netherlands Cancer Institute, Amsterdam, The Netherlands, Pooja Ghatalia, MD, Fox Chase Cancer Center, Philadelphia, PA, Joaquim Bellmunt, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, and, Aly-Khan Lalani, MD, McMaster University, Hamilton, Canada, as they discuss critical findings from ASCO GU 2026, including combination therapies, innovative approaches to bladder preservation, and novel biomarkers in prostate and renal cell carcinoma.

In this week’s VJOncology podcast, as part of Oesophageal Cancer Awareness Month in the UK, we are pleased to bring you the latest advances shaping the treatment landscape for oesophageal and gastroesophageal cancers. Join leading experts Yelena Janjigian, MD, Memorial Sloan Kettering Cancer Center, Berend van der Wilk, MD, Erasmus MC Cancer Institute, Kohei Shitara, MD, National Cancer Center Hospital East, and Ian Chau, MD, Royal Marsden Hospital, as they discuss pivotal data from key clinical trials across the disease spectrum. Our expert panel highlights how these data are refining first-line strategies, informing organ-preserving approaches, and advancing biomarker-driven therapies in oesophageal and gastroesophageal cancers.

In this week’s VJOncology podcast, we are delighted to bring you the latest advances in circulating tumor DNA (ctDNA)-informed monitoring and follow-up strategies in breast cancer. Join leading experts Wolfgang Janni, MD, University of Ulm, Ulm, Germany, Arielle Medford, MD, Massachusetts General Cancer Center, Boston, MA, Seth Wander, MD, PhD, Massachusetts General Hospital, Boston, MA, and Rinath Jeselsohn, MD, Dana-Farber Cancer Institute, Boston, MA, as they explore cutting-edge data from key studies including SURVIVE, LEADER, a Phase I/II trial of vepdegestrant, and PACE. Together, they discuss the evolving role of circulating tumor DNA in detecting molecular relapse, guiding early intervention strategies, monitoring treatment response, and predicting resistance across early and advanced ER+/HER2-negative and HR+/HER2-negative breast cancer settings.

In this week’s VJOncology podcast, we bring you key updates on the evolving landscape of checkpoint inhibition beyond PD-1 and PD-L1 across solid tumors. Join leading experts Jesus Fuentes-Antras, MD, NEXT Oncology Madrid, Madrid, Spain, Laurence Buisseret, MD, PhD, Institute Jules Bordet, Brussels, Belgium, and Yuxiang Ma, MD, PhD, Sun Yat-Sen University Cancer Center, Guangzhou, China, as they discuss novel bispecific and bifunctional immunotherapy strategies, first-in-human and early-phase clinical data, and emerging checkpoint inhibitor–ADC combinations shaping treatment paradigms in breast cancer, urothelial carcinoma, and other advanced malignancies.

In recognition of Cervical Cancer Awareness Month, this episode of VJOncology podcasts explores advances in cervical cancer prevention and treatment. We hear from three leading experts who discuss pivotal developments shaping clinical practice. Dr Domenica Lorusso from Fondazione IRCCS National Cancer Institute of Milan examines the breakthrough combination of immunotherapy and radiotherapy in locally advanced disease, highlighting practice-changing data from the KEYNOTE-A18 trial that established pembrolizumab plus chemoradiotherapy as the new standard of care for stage 3 cervical cancer. Dr Amanda Psyrri from National Kapodistrian University of Athens underscores the critical role of HPV vaccination in preventing not only cervical cancer but also HPV-associated oropharyngeal malignancies, particularly those caused by high-risk subtypes 16 and 18. Finally, Dr Alberto Farolfi from IRCCS Istituto Romagnolo per lo Studio dei Tumori shares real-world evidence on the addition of bevacizumab to pembrolizumab-chemotherapy regimens in advanced cervical cancer, demonstrating survival benefits without increased serious adverse events. This episode offers essential insights into the evolving landscape of cervical cancer management from prevention through advanced disease.

This podcast is available on the GI Cancer Channel on VJOncology, an independent medical education platform, which is supported by Takeda (Gold) and Gilead Sciences (Silver). Supporters have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given. This VJOncology podcast explores the evolving landscape of immunotherapy in gastrointestinal malignancies, spanning from perioperative to adjuvant settings across multiple tumor types. Findings from the Phase II KEYSTEP-008 platform trial are presented, focusing on optimizing pembrolizumab-based combinations in MSI-high, mismatch repair deficient metastatic colorectal cancer. In addition, emerging biomarkers for immunotherapy beyond microsatellite instability in colorectal cancer are explored, including results from the TAPUR trial evaluating dual checkpoint inhibition in patients with BRCA1/2 alterations. The historically challenging adjuvant setting in hepatocellular carcinoma is examined through insights from the KEYNOTE-937 trial evaluating immunotherapy after curative-intent treatment. Finally, experts discuss the NEOSUMMIT-01 trial and how perioperative immunotherapy is transforming treatment strategies for locally advanced gastric and gastroesophageal junction cancers. Together, these perspectives highlight immunotherapy's expanding therapeutic potential across the GI cancer spectrum.

In this week’s VJOncology podcast, we bring you key developments in novel approaches in immunotherapy refractory head and neck cancer. Join head and neck cancer expert Amanda Psyrri, MD, PhD, FACP, National Kapodistrian University of Athens, Athens, Greece, as she discusses on mechanisms of resistance to checkpoint inhibitors, strategies to overcome resistance such as antibody drug conjugates (ADCs) and tumor vaccines, as well as the trials assessing anti-TIGIT inhibitors.

In this week’s VJOncology podcast, the first of 2026, we bring you key updates in the use of artificial intelligence (AI) in oncology and how it will impact clinicians and patients alike. Join renowned experts Anita Grigoriadis, PhD, King’s College London, London, UK, Rosalind Picard, ScD, MIT Media Lab, Cambridge, MA, Jana Lipkova, PhD, University of California, Irvine, CA, and Roberto Salgado, MD, PhD, Peter MacCallum Cancer Centre, Melbourne, Australia as they comment on how to increase AI literacy for oncologists, identifying patients with high-risk lobular breast cancer with AI, and more.

In this episode of the VJOncology Podcast, we bring you key highlights from the San Antonio Breast Cancer Symposium 2025 (SABCS 2025). This curated episode features expert insights into practice-changing data across HER2-positive metastatic disease, hormone receptor–positive early breast cancer, and the growing role of artificial intelligence in risk stratification. Leading investigators discuss advances in targeted therapies, endocrine treatment optimization, and AI-driven tools that may refine prognostic assessment and clinical decision-making in breast cancer.

In this week’s VJOncology podcast, we will be covering highlights from ESMO 2025 in Berlin, Germany. Gain expert insights in the field of genitourinary cancers, including highly-anticipated trial results, emerging biomarkers in kidney cancer, and the evolving role of radionuclides in  prostate cancer. Join renowned speakers Andrea Necchi, MD, IRCCS San Raffaele Hospital and Scientific Institute, Milan, Italy, Sara Coca Membribes, MD, Barts Health NHS Trust, London, UK, Scott Tagawa, MD, MS, FACP, Weill Cornell Medical Center, New York, NY, Paul Nguyen, MD, MBA, Dana-Farber Cancer Institute, Boston, MA, as they discuss trials such as GDFather-NEO, CALYPSO, and more.

In this week’s VJOncology podcast, we have the pleasure to bring you key updates in gastrointestinal cancer at ESMO 2025, which we attended live in Berlin. Join esteemed experts Kohei Shitara, MD, National Cancer Center Hospital East, Kashiwa, Japan, Michele Reni, MD, IRCCS San Raffaele Scientific Institute, Milan, Italy, Stephen Lam Chan, MD, FRCP, Chinese University of Hong Kong, Hong Kong, China, and Anwaar Saeed, MD, University of Pittsburgh, Pittsburgh, PA, as they discuss ground-breaking trials such as FORTITUDE-101, CASSANDRA, STELLAR-303, and more.

In this episode of the VJOncology Podcast, we bring you four standout interviews from ESMO 2025 that are reshaping the way we think about lung cancer. From antibody-drug conjugates and bispecific T-cell engagers through novel HER2-targeted TKIs to tumour-immune microenvironment biomarkers, the treatment paradigm is evolving rapidly. Join us as we explore findings from the Phase III OptiTROP-Lung04 study of sacituzumab tirumotecan in EGFR-mutant non-small-cell lung cancer (NSCLC) post-TKI progression, safety analysis of DeLLphi-304: tarlatamab vs standard chemo in small-cell lung cancer (SCLC), the first-line Beamion LUNG-1 experience of zongertinib in advanced HER2-mutant NSCLC and biomarker insights from the ImmunoDriver-2 analysis. We’ll weave together how these advances hint at a future where molecular and immunologic profiling come together: identifying patients who will benefit most, integrating new treatment classes, and navigating safety/survivorship in more complex regimens. 

In this week’s podcast from VJOncology, leading experts share key insights from the 44th Congress of the European Society of Surgical Oncology (ESSO 44), held in Gothenburg, Sweden. The meeting brought together global specialists to discuss innovations in cancer surgery, including artificial intelligence, robotics, and fluorescence imaging. Beate Rau, MD, PhD, highlights advances across gastrointestinal and rectal cancers, as well as the role of intraperitoneal chemotherapy in gastric cancer. Marco Fiore, MD, discusses the evolving surgical approach to retroperitoneal sarcoma, while Piotr Rutkowski, MD, explores progress in melanoma management, from gene expression profiling to new targeted treatments. Gabrielle van Ramshorst, MD, outlines the essential skills for the next generation of colorectal surgeons, and Domenico D’Ugo, MD, reflects on the concept of the mesogastrium and its implications for radical gastric cancer surgery.

In this week’s VJOncology podcast, leading experts share the latest updates in ADCs in HER2-positive and metastatic breast cancer in recognition of Breast Cancer Awareness Month. Charles Geyer, MD, discusses pivotal results from the Phase III DESTINY-Breast05 trial, where trastuzumab deruxtecan (T-DXd) significantly improved invasive disease-free and disease-free survival versus trastuzumab emtansine (T-DM1) in high-risk HER2-positive early breast cancer, reducing the risk of brain metastases. Sara Tolaney, MD, MPH, highlights the practice-changing reduction in recurrence risk with T-DXd and comments on the expanding role of antibody–drug conjugates (ADCs) in earlier lines of therapy across breast cancer subtypes, referencing data from DESTINY-Breast09 and ASCENT-03. Finally, Erika Hamilton, MD, reviews the advancement of ADCs into the curative setting through DESTINY-Breast11 and discusses emerging combination strategies and first-line use in triple-negative breast cancer, emphasizing the growing importance of ADCs in modern breast cancer care.

In this week’s VJOncology podcast, leading experts share key updates presented at the ESMO 2025 Congress in Berlin, Germany. Sara Tolaney, MD, MPH, highlights the expanding role of ADCs in earlier lines of metastatic breast cancer, presenting data from the DESTINY-Breast09 and ASCENT-03 trials, and discusses results from DESTINY-Breast05, where trastuzumab deruxtecan demonstrated superior outcomes to trastuzumab emtansine in high-risk HER2-positive early breast cancer. Scott Tagawa, MD, reports findings from the PSMAddition trial of [177Lu]Lu-PSMA-617 in metastatic hormone-sensitive prostate cancer, showing improved radiographic progression-free survival. Antonio Passaro, MD, PhD, outlines data from the OptiTROP-Lung04 study of sacituzumab tirumotecan in EGFR-mutated NSCLC, establishing a new benchmark for TROP2-directed ADCs. Andrea Necchi, MD, discusses interim results from the RC48-C016 trial supporting disitamab vedotin plus toripalimab in HER2-expressing urothelial carcinoma, and Sapna Patel, MD, shares encouraging early findings on PRAME-directed TCR therapy in uveal melanoma.

In this week’s VJOncology podcast, leading experts share the latest updates in the management of hepatocellular carcinoma (HCC) in recognition of Liver Cancer Awareness Month. Stephen Lam Chan, MD, FRCP, discusses emerging immunotherapy and targeted approaches, including novel TIM3 and TIGIT inhibitors, and findings from the SIERRA study of durvalumab and tremelimumab in advanced HCC. Lorenza Rimassa, MD, reviews the CheckMate 9DW trial establishing nivolumab plus ipilimumab as a new standard of care, while Qi Cheng, PhD, highlights promising results from a Phase II study of irpagratinib plus atezolizumab in FGF19-positive HCC. Ciro Celsa, MD, PhD, shares real-world data from the DT-REAL study evaluating durvalumab with or without tremelimumab in unresectable HCC, confirming the regimen’s effectiveness in clinical practice. Finally, Marina Baretti, MD, presents encouraging findings from a Phase I study of a peptide vaccine targeting the DNAJB1-PRKACA fusion in fibrolamellar HCC.

In this week’s VJOncology podcast, we are joined by brain tumor experts Stephen Bagley, MD, MSCE, University of Pennsylvania, Philadelphia, PA, and Cecile Riviere-Cazaux, PhD, Mayo Clinic, Rochester, MN, as they discuss the latest updates in cerebrospinal fluid (CSF) liquid biopsies in brain tumors. They will comment on the rationale and challenges in CSF liquid biopsies in this space, current research in their clinical utility and what the future holds for this area.

In this week’s exclusive VJOncology podcast, we are joined by Javier Martín-Broto, MD, PhD, Fundación Jiménez Díaz University Hospital, Madrid, Spain, who shares expert insights on the evolving role of immunotherapy in sarcoma. He discusses the unique immunosensitivity of alveolar soft part sarcoma, the potential of combining checkpoint inhibitors with anti-angiogenic or anti-CTLA-4 agents, and encouraging results with TCR-T cell therapy in synovial sarcoma and myxoid liposarcoma. The role of biomarkers such as tertiary lymphoid structures (TLS) is also highlighted as a predictor of response to immunotherapy.

In this week’s VJOncology podcast, we have the pleasure to bring you key updates in lung cancer at IASLC 2025 World Conference on Lung Cancer (WCLC), which we attended live in Barcelona, Spain. Join experts John Varlotto, MD, Marshall University, Huntington, WV, Alessio Cortellini, MD, Bio-Medico University, Rome, Italy, Ana Baramidze, MD, PhD, Todua Clinic, Tbilisi, Georgia, Nicolas Girard, MD, Institut Curie, Paris, France, and Kenneth O'Byrne, MD, MB, BCh, Princess Alexandra Hospital, Brisbane, Australia, as they discuss pivotal trials in non-small cell lung cancer (NSCLC) such as the FLAURA2, and ACROSS 2 trials, developments in mesothelioma, and practice-changing data in small cell lung cancer (SCLC).

In this week’s podcast from VJOncology, three leading experts provide insights into the latest advances in precision medicine for head and neck cancer. Luigi Lorini of Humanitas Research Hospital discusses the evolving treatment landscape of immunotherapy in head and neck squamous cell carcinoma. Danny Rischin of the Peter MacCallum Cancer Centre presents findings from a Phase II trial evaluating fianlimab plus cemiplimab in patients with recurrent or metastatic PD-L1–expressing head and neck squamous cell carcinoma. Finally, Jun Ma from Sun Yat-sen University Cancer Center explores the future of immunotherapy in nasopharyngeal carcinoma beyond PD-1 and shares results from the Phase III DIAMOND trial of toripalimab with induction chemotherapy and radiotherapy, with or without concurrent cisplatin, in locoregionally advanced disease.

In this week’s VJOncology podcast, we will be joined by Rupert Bartsch, MD, Medical University of Vienna, Vienna, Austria, as he outlines current and emerging strategies for managing HER2-positive metastatic breast cancer after antibody–drug conjugate (ADC) therapy, with a focus on trastuzumab deruxtecan (T-DXd). He discusses the use of tucatinib-based regimens, mechanisms of resistance to agents such as trastuzumab emtansine (T-DM1), and approaches to treating brain metastases, drawing on evidence from trials. The importance of individualized treatment is highlighted, particularly in hormone receptor–positive disease, where CDK4/6 inhibitors may provide added benefit.

In this week’s installment of the VJOncology podcast, we will examine the cutting-edge applications of artificial intelligence in clinical oncology. This episode presents a curated series of expert insights into AI-driven tools for early detection, diagnostic precision, biomarker development, treatment guidance, and prognostic assessment. Leading clinicians and researchers discuss breast, sarcoma, kidney, gastric, and lung cancers, highlighting how AI is being integrated into clinical workflows, risk stratification, and patient-specific decision-making. This episode provides actionable knowledge on leveraging AI to improve diagnostic accuracy, optimize therapeutic strategies, and enhance patient outcomes across multiple tumor types.

Join leading GI cancer experts J. Randolph Hecht, UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA, Jasmine Mitchell, UCLA Santa Monica Medical Center, Santa Monica, CA, and Jingran Ji, UCLA Santa Monica Medical Center, Santa Monica, CA, as they share key insights from the most impactful gastrointestinal cancer updates presented at ASCO 2025. In this episode, they discuss pivotal trials including CHALLENGE (NCT00819208), demonstrating that structured exercise can improve disease-free survival in resected colon cancer; ATOMIC (NCT02912559), highlighting the role of adjuvant immunotherapy with atezolizumab in MSI-high colon cancer; and MATTERHORN (NCT04592913), where adding durvalumab to perioperative FLOT improved outcomes in gastric and gastroesophageal junction adenocarcinoma.

In this week's VJOncology podcast, we will be covering highlights from the American Society of Clinical Oncology (ASCO) Annual Meeting 2025 in Chicago, IL. Gain expert insight on exploratory biomarkers, treatment landscape shifts, and practice-changing trials from leading researchers in the field of genitourinary cancers. Join renowned speakers Angela Jia, Tian Zhang, Michael Harrison, Margaret Gatti-Mays, and Stefanie Zschaebitz, as they discuss Phase I/II trial results on neoadjuvant combination therapy for cisplatin-ineligible bladder cancer, and strides in personalized vaccines in metastatic prostate cancer.  

In this episode of the VJOncology podcast, we explore the evolving landscape of gynecologic cancer care with expert insights recorded at the 2025 ESMO Gynaecological Cancers Congress in Vienna. Ilana Cass, MD, Dartmouth-Hitchcock Medical Center, Lebanon, NH, discusses new data from the RUBY trial and the impact of dostarlimab in endometrial cancer. Christina Fotopoulou, MD, PhD, Imperial College London, London, UK, presents findings from the TRUST trial, highlighting the value of primary debulking surgery in advanced ovarian cancer. We also hear from Felix Hilpert, MD, Krankenhaus Jerusalem, Hamburg, Germany on overcoming treatment hesitancy in elderly ovarian cancer patients, and Angeles Secord, MD, Duke Cancer Institute, Durham, NC shares promising results from the PICCOLO study of mirvetuximab soravtansine in FRα-positive disease. Finally, Domenica Lorusso, MD, PhD, Fondazione IRCCS National Cancer Institute of Milan, Milan, Italy, outlines a new standard of care for stage 3 cervical cancer, combining radiotherapy with pembrolizumab as supported by KEYNOTE-A18. Tune in for expert commentary and clinical implications that could shape the future of gynecologic oncology.

In this weeks podcast from VJOncology, five leading experts share updates and insights on the evolving landscape of precision medicine in sarcoma. Robin Jones discusses the complexities of implementing precision medicine and presents results from a Phase III trial of catequentinib in advanced leiomyosarcoma. Javier Martín-Broto explores recent advances in immunotherapy and shares findings from Cohort 7A of the ImmunoSarc2 trial, evaluating epirubicin and ifosfamide plus nivolumab in undifferentiated pleomorphic sarcoma. Nadia Hindi highlights Cohort 2, which assessed sunitinib and nivolumab in extraskeletal myxoid chondrosarcoma. Ramya Ramaswami addresses unmet needs in Kaposi sarcoma and presents data from a Phase I trial of efineptakin alfa in patients with and without HIV. Finally, Brian Van Tine discusses a Phase II trial of olaparib and temozolomide in advanced uterine leiomyosarcoma.

In this weeks VJOncology podcast, we have the pleasure to bring you key updates in CAR-T and cellular therapies in brain tumors. Gain expert insights on landmark trials, treatment advances, and shifting screening practices from some of the foremost voices in the field. Topics of discussion include a Phase I trial of intracranial B7H3-directed CAR-T cell therapy in patients with recurrent glioblastoma, effective strategies in anti- glioblastoma CAR-T cells, and dendritic cell therapy in recurrent glioblastoma.

This week’s VJOncology podcast episode highlights four breakthrough studies from ESMO GI 2025 in Barcelona, Spain, featuring expert insights on gastrointestinal cancer advances. Coverage includes the EXPEL PANC study combining BXCL701 with pembrolizumab for pancreatic cancer, SIERRA study safety data on the STRIDE regimen for hepatocellular carcinoma, TALENTACE trial results combining TACE with atezolizumab plus bevacizumab, and updated MATTERHORN study data on perioperative immunotherapy for gastric cancer. Leading oncologists share perspectives on these game-changing developments reshaping GI cancer treatment live from Barcelona, Spain.

Join esteemed experts Joao Victor Alessi, Hospital Sírio-Libanês, Sao Paolo, Brazil, and Alessandro Di Federico, Dana-Farber Cancer Institute, Boston, MA, as they discuss the most anticipated updates in lung cancer presented at ASCO 2025, as they comment on ground-breaking trials and provide their insights on the significance of the findings and updates. In this episode, they comment on the potential of new agents like tarlatamab, and pivotal trials such as the OptiTROP-Lung03 trial of sacituzumab tirumotecan in EGFR-mutated non-small cell lung cancer (NSCLC), the CheckMate 816 trial of neoadjuvant nivolumab plus chemotherapy, and the ALNEO trial of alectinib in ALK-positive NSCLC.

Join our experts as they delve into the latest advancements in breast cancer presented at ASCO 2025, as they comment on highly anticipated trials and gives their perspectives on the significance of the findings and updates. In this episode, Kevin Kalinsky, Emory University Hospital, Atlanta, GA, and Komal Jhaveri, Memorial Sloan Kettering Cancer Center, New York, NY, receive updates on trials presented at this year’s ASCO, including the ASCENT-04 trial (NCT05382286) of sacituzumab govitecan and pembrolizumab in PD-L1-positive triple-negative breast cancer (TNBC) and the DESTINY-Breast09 trial (NCT04784715) of first-line trastuzumab deruxtecan (T-DXd) and pertuzumab in patients with HER2+ breast cancer.